Published • loading... • Updated
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
- Roche announced the European Union IVDR approval for the VENTANA MMR RxDx Panel, an immunohistochemistry companion diagnostic test that identifies mismatch repair status in cancer patients.
- Mismatch repair is a biological process that corrects errors in a person's genetic code to prevent mutations that may cause cancer.
- The VENTANA MMR RxDx Panel aids clinicians in making informed decisions and expands access to therapies across multiple solid tumor types.
- This IVDR approval is a label expansion of Roche's existing on-market VENTANA MMR RxDx Panel and allows its use as a companion diagnostic for various therapies and cancers.
Insights by Ground AI
15 Articles
15 Articles
Montana Standard+14 Reposted by 14 other sources
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapiesBy evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option…
Coverage Details
Total News Sources15
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
